The role of vascular smooth muscle cell membrane-bound thrombomodulin in neointima formation

Wang, Kuan Chieh; Chen, Po Sheng; Chao, Ting‐Hsing; Luo, Chuannan; Chung, Hsien-Ching; Tseng, Shuo Yen; Huang, Ting; Lin, Ying Li; Shi, Guey Yueh; Wu, Hua; Li, Yi Heng

doi:10.1016/j.atherosclerosis.2019.05.019

Cited by 5 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is accomplished by enhancing the formation of new blood vessels, inhibiting endothelial cell apoptosis, preventing the expression of adhering molecules, and controlling endothelial cell activation. , Calponin, a SMC-specific contractile marker, expresses in vascular SMCs with a normal contractile phenotype. Upon vascular injury, a proinflammatory phenotype develops in the medial SMCs with decreased contractile marker expression. , In this study, the released BIBR-277 had a beneficial effect on endothelial cell recovery and the inhibition of SMCs in vivo .…”

Section: Resultsmentioning

confidence: 56%

“…Upon vascular injury, a proinflammatory phenotype develops in the medial SMCs with decreased contractile marker expression. 53,54 In this study, the released BIBR-277 had a beneficial effect on endothelial cell recovery and the inhibition of SMCs in vivo. BIBR-277 has been shown to have beneficial metabolic effects by increasing insulin sensitivity and improving the plasma lipid profile.…”

Section: ■ Resultsmentioning

confidence: 63%

See 1 more Smart Citation

Hybrid Core–Shell Nanofibrous Scaffolds/Stents Deliver Angiotensin II Receptor Blocker to Treat Diabetic Artery Disease

Lee

Hsieh

Roth

et al. 2022

ACS Appl. Polym. Mater.

View full text Add to dashboard Cite

Most patients with diabetes suffer from impaired endothelial function and neointimal thickening, which contribute to arterial atherosclerosis and increase the frequency of adverse cardiovascular events. Angiotensin II receptor blockers (BIBR-277; telmisartan) exhibit distinct peroxisome proliferator−activated receptor-γ activation, which is beneficial in the treatment of arterial diseases and atherosclerosis. This investigation proposes the use of biodegradable core−shell nanofibers for the sustained and local delivery of BIBR-277 to the wall of a balloon-injured artery in the abdominal aorta of diabetic rabbits. Poly(D,L)-lactide-co-glycolide (50:50) and solutions of BIBR-277 or Dulbecco's phosphate-buffered saline were electrospun as nanofibrous tubes and subsequently mounted on bare-metal stents. These biodegradable nanofibers released BIBR-277 for 28 days without any observable burst effect. Moreover, the drug-loaded nanofibers sustained the local delivery of BIBR-277 and increased the migration of endothelial progenitor cells in vitro while both promoting reendothelialization and decreasing the proliferation of smooth muscle cells in vivo. In conclusion, herein, a core−shell scaffold that incorporates BIBR-277-loaded nanofibers is demonstrated to sustainably deliver cardiovascular drugs and, in doing so, provides an insight into the management of the accelerated atherosclerotic vascular disease in patients with diabetes.

show abstract

Section: Resultsmentioning

confidence: 56%

Section: ■ Resultsmentioning

confidence: 63%

Hybrid Core–Shell Nanofibrous Scaffolds/Stents Deliver Angiotensin II Receptor Blocker to Treat Diabetic Artery Disease

Lee

Hsieh

Roth

et al. 2022

ACS Appl. Polym. Mater.

View full text Add to dashboard Cite

show abstract

“…TM is an important marker for EC damage ( 45 ). TM is released into the blood after vascular ECs are damaged, and the degree of damage is positively related to blood TM levels ( 46 ). C-P can indirectly reflect the concentration of insulin, and abnormally increased insulin content, together with insulin resistance, is an independent risk factor contributing to the development of CSVD ( 47 ).…”

Section: Biochemical Markers and Influencing Factorsmentioning

confidence: 99%

Cerebral Small Vessel Disease: Neuroimaging Features, Biochemical Markers, Influencing Factors, Pathological Mechanism and Treatment

et al. 2022

View full text Add to dashboard Cite

Cerebral small vessel disease (CSVD) is the most common chronic vascular disease involving the whole brain. Great progress has been made in clinical imaging, pathological mechanism, and treatment of CSVD, but many problems remain. Clarifying the current research dilemmas and future development direction of CSVD can provide new ideas for both basic and clinical research. In this review, the risk factors, biological markers, pathological mechanisms, and the treatment of CSVD will be systematically illustrated to provide the current research status of CSVD. The future development direction of CSVD will be elucidated by summarizing the research difficulties.

show abstract

Recent Advances in Cell‐Based Nanotherapy for Cardiovascular Diseases

Hao

2023

Macromolecular Bioscience

View full text Add to dashboard Cite

Cell‐based nanotherapy holds great potential to transform diagnosis and treatment patterns for human diseases, especially for cardiovascular diseases (CVDs). Surface coating with cell membrane has become a powerful strategy for functionalization of therapeutic nanoparticles to achieve biological performances of superior biocompatibility, immune evasion, and specificity. Additionally, extracellular vesicles (EVs) play key roles in the progression of CVDs with their ability of transferring cargos to distant tissues, thus emerging as an appealing option for the diagnosis and therapy of CVDs. In this review, recent progress in cell‐based nanotherapy for CVDs is summarized, and different sources of EVs and biomimetic nanoplatforms derived from natural cells are highlighted. Meanwhile, their promising biomedical applications in the diagnosis and targeted treatment of different CVDs are also provided, followed by a discussion of their potential challenges and future prospects.

show abstract

The role of vascular smooth muscle cell membrane-bound thrombomodulin in neointima formation

Cited by 5 publications

References 35 publications

Hybrid Core–Shell Nanofibrous Scaffolds/Stents Deliver Angiotensin II Receptor Blocker to Treat Diabetic Artery Disease

Hybrid Core–Shell Nanofibrous Scaffolds/Stents Deliver Angiotensin II Receptor Blocker to Treat Diabetic Artery Disease

Cerebral Small Vessel Disease: Neuroimaging Features, Biochemical Markers, Influencing Factors, Pathological Mechanism and Treatment

Recent Advances in Cell‐Based Nanotherapy for Cardiovascular Diseases

Contact Info

Product

Resources

About